Navigation Links
PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
Date:4/13/2011

ANNAPOLIS, Md., April 13, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has completed dosing in a U.S. Phase I clinical trial of its fully human anti-toxin monoclonal antibody, Valortim®, being developed for the prevention and treatment of inhalational anthrax.

The randomized, placebo-controlled, double-blind Phase I clinical trial was designed to evaluate single escalating doses of 1, 5, or 10 mg/kg of Valortim® (or placebo) administered intravenously over a 120 minute infusion period.  A total of 28 participants, all healthy male and female volunteers between the ages of 18 and 60 years, were enrolled in the study.

"We have completed dosing of all 28 subjects and are pleased to report that no infusion-related adverse reactions have been observed in the current Phase I trial.  We anticipate that safety follow-up will be completed in the third quarter of 2011 with final unblinded results available later in the year," remarked Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer.

"This represents an important step in the development of Valortim®, which is being developed to meet the criteria for stockpiling in the U.S. Strategic National Stockpile," continued Dr. Fuerst.  "In preclinical animal studies Valortim® has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection when administered at the time of exposure, at doses as low as 1.0 mg/kg.  When administered to rabbits after the development of symptoms, Valortim® also improved survival as late as 48 hours post-exposure as compared to control animals.  We look forward to completing the Phase I clinical trial, which will provide important information about the IV dosing schedule for Valortim® in humans."  

The Valortim® project has been conducted with
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... , Dec. 23, 2014 In response to ... Association of Sierra Leone , Direct Relief ... for the treatment of local health workers who ... a new dedicated Ebola care center was constructed for foreign ... facility is not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... To foster and support the next generation of lupus ... awarded summer fellowships to five young investigators who will ... lupus investigator. Named after the daughter of former ... Memorial Student Summer Fellowship program has supported the work ...
... Noted At Day 3 And All Subsequent Study Visits - ... Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today that positive ... the treatment of patients with schizophrenia have been published in ... double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, ...
Cached Medicine Technology:Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students 2Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... coordinate gene expression is a long-standing goal of ... multiple vertebrate or invertebrate // species holds promise ... dynamic interplay between a gene and its transcriptional ... based on the hypothesis that functionally important sequences ...
... all aspects of human behaviour; they impact upon the foods ... or avoid and the people with whom we spend time ... it has been proposed that the brain uses it as ... avoidance behaviors. Stimulus evaluation is also thought to be immediate, ...
... 70 percent of the children who live in non-fluoridated ... adequately fluoridated water. , ,These findings were arrived ... children. Jason Armfield, a researcher at the Australian Centre ... was categorical in saying that the study highlighted the ...
... for fish food to be cooked the right way to harness ... is as important as the amount of fat and calories in ... facts? Just one piece of batter-dipped fish has 170 calories and ... stuff, hushpuppies and coleslaw will probably give you 1,240 calories and ...
... suggested that therapeutics based on monoclonal antibodies (mAbs) are ... small molecule predecessors. According to a study completed by ... so fare appear to be profitable. That means mAbs ... billion to $1.8 billion cost of development and marketing. ...
... materialized by increasing cigarette taxes, raising the smoking age and ... youth smoking according to a researchers. // This ... people addicted to this habit. It is time that lawmakers ... research shows that reducing smoking initiation in youth is likely ...
Cached Medicine News:Health News:Evoprinter, a multigenomic comparative tool for rapid identification of functionally important DNA 2Health News:Conditioning preferences in children 2Health News:Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs 2Health News:Lawmakers alerted on new tobacco control policies by research team 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: